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The rapid emergence and spread of antimicrobial 
resistance among common pathogens in many Euro- 
pean countries and elsewhere has prompted the Society 
of Infectious Diseases of the Netherlands and Flanders 
together with the professional societies of medical 
microbiologists and of hospital pharmacists to join 
forces in a separate Working Party on Antibiotic Policy, 
its acronym in Dutch is SWAB. 
SWAL3 was founded at the end of 1996 with the 
major goal of contributing to the quality of health care 
in The Netherlands, and beyond, through efforts that 
help to stem, and even reverse, the rising tide of 
widespread resistance to antimicrobial agents of value 
in the management of infectious diseases. Since the 
emergence of antimicrobial resistance can best be 
described as multiple, linked epidemics that affect 
large populations (of humans, animals and, of course, 
microbes), SWAB’S efforts make use of the time- 
honored epidemiologic tools of surveillance and 
surveillance-driven interventions. 
Surveillance of antimicrobial resistance is currently 
rather fragmented and limited in scope, and often does 
not provide hard quantitative data. Lack of standard- 
ization of surveillance methodology further hampers 
the aggregation of resistance data that is available. 
Although the misuse of antibiotics is widely believed to 
be the single major determinant driving the resistance 
epidemic, training of medical and veterinary students 
and continued education of physicians in the appro- 
priate use of these agents is felt to be insufficient. 
Therefore, SWAB’S first projects aim to provide 
educational tools in the form of national antibiotic use 
tests, and in the publication of a national blueprint for 
an antibiotic policy that can help fellow physicians and 
pharmacists involved in making such policies at the 
local level in hospitals and other stations where 
antibiotics are dispensed. Also, our local and national 
surveillance programs for antimicrobial resistance need 
to be overhauled, amended to provide the quantitative 
data, and collated to provide insight in the ongoing 
changes in the susceptibilities of common pathogens to 
relevant groups of antimicrobial agents. Preferably, 
resistance data from The Netherlands should be of such 
quality that they can become part of one or more of 
the international resistance sureveillance networks 
presently being developed in Europe and elsewhere. 
The SWAB initiative has been welcomed by the 
government of The Netherlands, and the first SWAB 
projects have been funded by grants from the Ministry 
of Health, Welfare and Sport. The SWAB members 
participate in the recently started Working Party on 
Antibiotic Policy of the European Society of Medical 
Microbiology and Infectious Diseases. 
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We would like to introduce the Society for Health Care 
Epidemiology of America (SHEA) to the mainly 
European readers of CMI, of whom a great number 
probably shares our interest in (nosocomial) infections 
and their prevention. The lack of knowledge on both 
sides of the Atlantic about what others do or want 
to achieve certainly results in missed chances for 
cooperation and a waste of economic and mental 
resources. 
Worldwide nosocomial infection rates are in- 
creasing, related in part to changes in the patient 
population and new invasive diagnostic and therapeutic 
procedures that promote new infection problems. 
Development of antibiotic resistance in organisms that 
we believed to be under control just years ago, and the 
consequent spread of these multiresistant pathogens 
throughout healthcare institutions and the community 
is a daily concern for physicians, nurse epidemiologists 
and infection control practitioners around the globe. 
How can we meet this challenge, given that infection 
control services must meet the budgetary constraints of 
modern health economics? 
Exchange of state-of-the-art information on patho- 
genesis, epidemiology, treatment and prevention of 
infectious diseases seems to be an important step 
towards the solution of European and American 
problems. As in other specialities, policies and measures 
used in infection control show large variations among 
different nations. These differences are based not only 
on legal issues, national guidelines and monetary 
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